See more : China Life Insurance Company Limited (LFC) Income Statement Analysis – Financial Results
Complete financial analysis of Adjuvant Holdings Co.,Ltd. (4929.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adjuvant Holdings Co.,Ltd., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
- Sharp Corporation (SHCAY) Income Statement Analysis – Financial Results
- Anhui Gujing Distillery Co., Ltd. (200596.SZ) Income Statement Analysis – Financial Results
- Wenye Group Holdings Limited (1802.HK) Income Statement Analysis – Financial Results
- Kirin Group Holdings Limited (8109.HK) Income Statement Analysis – Financial Results
- Zonzia Media, Inc. (ZONX) Income Statement Analysis – Financial Results
Adjuvant Holdings Co.,Ltd. (4929.T)
Industry: Household & Personal Products
Sector: Consumer Defensive
Website: https://www.adjuvant.co.jp
About Adjuvant Holdings Co.,Ltd.
Adjuvant Holdings Co.,Ltd. engages in the research, development, production, and sale of cosmetics in Japan. The company offers skin care products, including cleansing products, face washes, lotions, beauty essences, masks, moisturizing creams, makeup bases, makeups, and body care products; hair care products comprising shampoos, treatments, scalp cleansing products, scalp lotions, and styling products; and other products. It serves hairdressing salons, barber shops, and esthetic salons. The company was formerly known as Adjuvant Cosme Japan Co.,Ltd. and changed its name to Adjuvant Holdings Co.,Ltd. in September 2021. Adjuvant Holdings Co.,Ltd. was founded in 1990 and is headquartered in Kobe, Japan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.44B | 4.38B | 4.43B | 4.89B | 4.67B | 5.16B | 5.10B | 4.77B | 4.40B | 4.50B | 4.57B | 4.47B | 4.14B |
Cost of Revenue | 1.58B | 1.46B | 1.49B | 1.89B | 1.86B | 2.00B | 1.90B | 1.76B | 1.59B | 1.63B | 1.58B | 1.59B | 1.41B |
Gross Profit | 2.86B | 2.92B | 2.94B | 3.00B | 2.81B | 3.16B | 3.20B | 3.01B | 2.81B | 2.87B | 2.99B | 2.88B | 2.73B |
Gross Profit Ratio | 64.45% | 66.61% | 66.45% | 61.35% | 60.12% | 61.23% | 62.80% | 63.07% | 63.82% | 63.73% | 65.41% | 64.36% | 65.98% |
Research & Development | 179.83M | 181.00M | 173.00M | 151.00M | 161.00M | 146.00M | 156.69M | 142.42M | 110.53M | 54.00M | 43.00M | 36.00M | 0.00 |
General & Administrative | 182.00M | 167.00M | 164.00M | 242.00M | 248.00M | 220.00M | 241.00M | 221.00M | 176.00M | 179.00M | 179.00M | 192.00M | 0.00 |
Selling & Marketing | 574.00M | 306.00M | 232.00M | 253.00M | 401.00M | 428.00M | 369.00M | 373.00M | 346.00M | 376.00M | 396.00M | 365.00M | 0.00 |
SG&A | 2.68B | 2.68B | 2.55B | 2.70B | 3.00B | 2.99B | 2.54B | 2.35B | 2.05B | 2.14B | 1.99B | 1.89B | 0.00 |
Other Expenses | 0.00 | 7.08M | -9.06M | 22.84M | 8.17M | 72.80M | 8.34M | 7.94M | 66.87M | 1.74M | -578.00K | -12.16M | 16.27M |
Operating Expenses | 2.86B | 2.68B | 2.55B | 2.70B | 2.99B | 2.99B | 2.70B | 2.49B | 2.16B | 2.14B | 1.99B | 1.89B | 1.80B |
Cost & Expenses | 4.44B | 4.14B | 4.04B | 4.59B | 4.86B | 4.99B | 4.60B | 4.25B | 3.75B | 3.77B | 3.57B | 3.48B | 3.21B |
Interest Income | 1.08M | 1.28M | 3.85M | 3.90M | 3.82M | 6.21M | 5.18M | 3.84M | 3.46M | 2.24M | 1.52M | 322.00K | 231.00K |
Interest Expense | 0.00 | 0.00 | 3.85M | 40.00K | 101.00K | 191.00K | 470.00K | 880.00K | 43.00K | 0.00 | 2.04M | 11.08M | 12.79M |
Depreciation & Amortization | 125.41M | 108.85M | 110.43M | 110.64M | 117.60M | 98.86M | 97.28M | 95.37M | 77.69M | 84.63M | 81.95M | 76.61M | 80.18M |
EBITDA | 124.00M | 697.06M | 500.79M | 292.22M | -44.61M | 282.07M | 608.54M | 634.89M | 671.79M | 1.18B | 1.09B | 1.06B | 994.66M |
EBITDA Ratio | 2.79% | 0.42% | 10.44% | 8.92% | -0.66% | 6.79% | 11.90% | 13.09% | 17.91% | 23.09% | 23.89% | 23.79% | 25.06% |
Operating Income | -1.43M | 232.69M | 390.36M | 292.93M | -184.62M | 169.79M | 500.46M | 519.06M | 647.03M | 733.90M | 1.00B | 988.65M | 938.92M |
Operating Income Ratio | -0.03% | 5.32% | 8.82% | 6.00% | -3.95% | 3.29% | 9.82% | 10.88% | 14.70% | 16.30% | 21.92% | 22.12% | 22.65% |
Total Other Income/Expenses | 16.72M | 355.53M | 49.18M | -111.40M | 22.31M | 13.24M | 10.34M | 19.59M | -52.97M | -195.75M | 1.09M | -13.45M | -37.21M |
Income Before Tax | 15.30M | 588.21M | 439.54M | 181.53M | -162.30M | 183.02M | 510.79M | 538.64M | 594.06M | 538.25M | 1.00B | 975.21M | 901.70M |
Income Before Tax Ratio | 0.34% | 13.44% | 9.93% | 3.72% | -3.47% | 3.54% | 10.02% | 11.29% | 13.50% | 11.95% | 21.95% | 21.82% | 21.75% |
Income Tax Expense | 115.16M | 184.57M | 46.36M | 39.15M | 65.62M | 157.96M | 199.77M | 208.11M | 327.96M | 491.21M | 431.44M | 441.92M | 625.45M |
Net Income | -99.87M | 403.64M | 393.18M | 142.38M | -227.93M | 25.06M | 311.02M | 330.54M | 266.10M | 47.04M | 571.73M | 533.29M | 276.25M |
Net Income Ratio | -2.25% | 9.22% | 8.88% | 2.91% | -4.88% | 0.49% | 6.10% | 6.93% | 6.05% | 1.04% | 12.51% | 11.93% | 6.66% |
EPS | -12.49 | 50.46 | 49.13 | 17.83 | -28.63 | 3.16 | 39.32 | 41.72 | 33.83 | 6.08 | 76.10 | 85.92 | 51.34 |
EPS Diluted | -12.49 | 50.46 | 49.08 | 17.76 | -28.63 | 3.14 | 39.09 | 41.49 | 33.44 | 5.96 | 73.81 | 82.12 | 51.34 |
Weighted Avg Shares Out | 8.00M | 8.00M | 8.00M | 7.99M | 7.96M | 7.94M | 7.91M | 7.92M | 7.87M | 7.73M | 7.51M | 6.21M | 5.38M |
Weighted Avg Shares Out (Dil) | 8.00M | 8.00M | 8.01M | 8.02M | 7.96M | 7.98M | 7.96M | 7.97M | 7.96M | 7.89M | 7.75M | 6.49M | 5.38M |
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
Devoir de vigilance : TotalEnergies regrette le refus par les ONG de la médiation proposée par le Tribunal judiciaire de Paris
Safety Management Group To Exhibit At The NSC Safety Congress & Expo
Berkshire Hathaway Specialty Insurance Promotes Two Casualty Leaders in the UK
Dr. Deborah Gross Answers the Call
Fidelity® Study: More Than 4 in 10 Working Caregivers May Be Forced to Choose Between Their Job and Caregiving in the Coming Year
Pathway Healthcare’s Winter Storm Response
Source: https://incomestatements.info
Category: Stock Reports